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Fully Percutaneous Technique for Transaxillary Implantation of the Impella CP
In recent years, mechanical circulatory support devices have undergone tremendous design improvements, and they are now used frequently as bridges to recovery, as destination therapy, or for transplantation (1). Unfortunately, when placed via the femoral approach, such devices still require persistent bed rest, which limits rehabilitation. The Impella CP (Abiomed, Danvers, Massachusetts) facilitates blood flow from the left ventricle to the ascending aorta using an axial pump and can augment cardiac output by as much as 3.5 l/min. For placement via the upper extremity vessels, the standard technique involves surgical cut-down and end-to-side graft anastomosis for the 14-F delivery sheath and thus requires coordination of an anesthesiologist, a surgeon, and a hybrid operating room with fluoroscopic capabilities. In contrast, a fully percutaneous upper extremity approach in a standard catheterization laboratory bypasses these strategic challenges and facilitates earlier patient rehabilitation.
In this technical communication, we provide a description of a direct percutaneous technique for transaxillary insertion of an Impella CP.
Conscious sedation, topical anesthesia, and thera- Between dilator exchanges, the peripheral balloon provides temporary hemostasis (Online Figure 1C) . Thus, to explant the device, a 6-F sheath is placed in the common femoral artery. A 5-F JR4 diagnostic catheter is then advanced into the left SCA, and angiography is performed. A 0.018-inch wire is advanced through the JR4 catheter into the distal brachial artery, and a similar 8-to 12-mm peripheral balloon is passed over the 0.018-inch wire into the mid-left SCA. The Impella CP is turned to P2 and withdrawn from the left ventricle into the ascending aorta. It is then switched to P0 (off) and pulled into the left SCA until the outflow port is partway externalized. During this time, the peripheral balloon is inflated (1 to 3 atm) to obstruct blood flow into the inflow port of the Impella (Online Figure 5A ).
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Through the externalized outflow cannula, a 0.035-inch short J-wire is advanced out of the inflow port and into the left axillary/subclavian artery (Online Figure 5B) . The Impella CP device and the repositioning sheath are then completely removed from the body. At this point, the vessel is closed using a Perclose or Prostar device (Abbott Vascular). The peripheral balloon is deflated, and the skin site is Letters to the Editor J U N E 1 3 , 2 0 1 6 : 1 1 9 5 -2 0 0 inspected for superficial hemostasis. Angiography is repeated to demonstrate vessel patency and hemostasis. All balloons, wires, and catheters are removed in standard fashion. A single skin stitch is placed at the left axillary puncture site using 3-0 Vicryl (Ethicon, Somerville, New Jersey), and the area is covered with Steri-Strips (3M, Minneapolis, Minnesota) (Online Figure 5C ).
In our preliminary experience with percutaneous access of the axillary artery, suture closure has been very successful as confirmed by completion angiography. One patient had mild residual contrast extravasation noted at the arteriotomy following explantation and was treated with 2 min of balloon tamponade to achieve hemostasis. In another case, regaining wire access to the vessel was unsuccessful, and a covered stent graft was used.
We have successfully implanted the Impella CP via the direct percutaneous transaxillary technique described in 8 patients (7 via the left and 1 via the right axillary artery). There were no unsuccessful attempts. The duration of support ranged from 1 to 22 days. In 4 patients, explantation was eventually indicated and achieved percutaneously without complications. For the other patients, 1 proceeded to heart transplantation (with Impella explant at that time), and 3 died prior to removal. (For patient descriptions, see Online Table 1 ).
No neurovascular complications were noted in the upper extremity in any of our cases. No access-related hematomas were noted. All patients who received Impella support for >1 day participated in physical therapy. For some, this included walking while pushing the Impella console. We found device position to be quite stable, with little evidence of migration, even in patients who were maintained on the Impella for >2 weeks. Additionally, we did not see any evidence of early or late insult to the brachial plexus, which is consistent with national experience accessing the subclavian vein for central venous catheters (2).
We have described a technique for percutaneous implantation and explantation of the Impella CP device using a left or right transaxillary approach that is both safe and feasible, even in critically ill patients. This technique presents multiple clinical advantages over traditional femoral access, as highlighted here. To the best of our knowledge, ours is the first technical description illustrating a fully percutaneous transaxillary technique using the Impella CP device. Further work is needed in this domain with a larger patient population to demonstrate the safety profile and clinical advantages of our technique. 
